Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Recurrent Uterine Corpus Carcinoma
Conditions
Brief summary
This phase II trial studies the side effects and how well cediranib maleate works in treating patients with endometrial cancer that has failed to respond to initial chemotherapy or has come back after surgery, radiation therapy, or other forms of treatment. Cediranib maleate may stop the growth of tumor cells by blocking proteins made by tumors that can stimulate growth of tumor cells as well as blood vessels in and around tumors.
Detailed description
PRIMARY OBJECTIVES: I. To assess the activity of cediranib (cediranib maleate) in patients with either persistent or recurrent endometrial carcinoma. II. To determine the frequency and degree of toxicity of cediranib as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version (v.)4.0 in this cohort of patients. SECONDARY OBJECTIVES: I. To determine the duration of progression-free survival and overall survival. II. To estimate the probability of response without restriction on the duration of response documentation since study enrollment. TERTIARY OBJECTIVES: I. To determine if the response to cediranib correlates with high-expression of its receptor targets (e.g., vascular endothelial growth factor receptor \[VEGFR\] \[1, 2, 3\] and platelet derived growth factor receptor \[PDGFR\]). II. To determine if the response to cediranib correlates with high endogenous circulating plasma levels of VEGFA, low-levels of its endogenous inhibitor, soluble fms-related tyrosine kinase 3 (sFlt-1) (the truncated, circulating portion of VEGFR-1), or circulating tissue factor (TF) or circulating prostate apoptosis response-4 (Par-4), both potential markers of tumor progression. III. To determine if a high-expression of VEGFA on pre-treatment tumor specimens correlates with response to cediranib. IV. To determine if expression of phosphorylated mitogen activated protein kinase (ERK) 1 and 2, c-Jun, signal transducer and activator of transcription 3 (Stat3), protein kinase C (PKC), and phosphorylated ribosomal protein S6 (p70S6) kinase correlates with resistance or sensitivity to cediranib. OUTLINE: Patients receive cediranib maleate orally (PO) daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Interventions
DRUGCediranib Maleate
Given PO
OTHERLaboratory Biomarker Analysis
Correlative studies
Sponsors
NRG Oncology
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have recurrent or persistent endometrial carcinoma, which is refractory to curative therapy or established treatments; histologic confirmation of the original primary tumor is required * Patients with the following histologic epithelial cell types are eligible: endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.), mucinous adenocarcinoma, squamous cell carcinoma, and transitional cell carcinoma * All patients must have measurable disease; measurable disease is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1); measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be \>= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or \>= 20 mm when measured by chest x-ray; lymph nodes must be \>= 15 mm in short axis when measured by CT or MRI * Patients must have at least one target lesion to be used to assess response on this protocol as defined by RECIST version 1.1; tumors within a previously irradiated field will be designated as non-target lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy * Patients must not be eligible for a higher priority Gynecologic Oncology Group (GOG) protocol, if one exists; in general, this would refer to any active GOG Phase III protocol or Rare Tumor protocol for the same patient population * Patients who have received one prior regimen must have a GOG performance status of 0, 1, or 2; patients who have received two prior regimens must have a GOG performance status of 0 or 1 * Recovery from effects of recent surgery, radiotherapy, or chemotherapy * Patients should be free of active infection requiring antibiotics (with the exception of uncomplicated urinary tract infection \[UTI\]) * Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration * Any other prior therapy directed at the malignant tumor must be discontinued at least three weeks prior to registration * Patients must have had one prior chemotherapeutic regimen for management of endometrial carcinoma; initial treatment may include chemotherapy, chemotherapy and radiation therapy, and/or consolidation/maintenance therapy; chemotherapy administered in conjunction with primary radiation as a radio-sensitizer WILL be counted as a systemic chemotherapy regimen * Patients are allowed to receive, but are not required to receive, one additional cytotoxic regimen for management of recurrent or persistent disease according to the following definition: cytotoxic regimens include any agent that targets the genetic and/or mitotic apparatus of dividing cells, resulting in dose-limiting toxicity to the bone marrow and/or gastrointestinal mucosa * Note: Patients on this non-cytotoxic study are allowed to receive one additional cytotoxic chemotherapy regimen for management of recurrent or persistent disease, as defined above; however, due to the novel nature of biologic compounds, patients are encouraged to enroll on second-line non-cytotoxic studies prior to receiving additional cytotoxic therapy * Patients must have NOT received any non-cytotoxic chemotherapy for management of recurrent or persistent disease; prior hormonal therapy is allowed * Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl * Platelets greater than or equal to 100,000/mcl * Creatinine less than or equal to 1.5 x institutional upper limit normal (ULN) or creatinine (Cr) clearance \>= 60 ml/min * Bilirubin less than or equal to 1.5 x upper limit of normal (ULN) * Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase \[AST\]) less than or equal to 2.5 x ULN * Alkaline phosphatase less than or equal to 2.5 x ULN * Neuropathy (sensory and motor) less than or equal to grade 1 * Urine protein creatinine (UPC) ratio must be \< 1.0 gm * If UPC ratio \>= 1, collection of 24-hour urine measurement of urine protein is recommended * Prothrombin time (PT) such that international normalized ratio (INR) is =\< 1.5 x ULN (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin) and a partial thromboplastin time (PTT) =\< 1.5 x ULN * Patients must have an amylase and lipase =\< ULN * Patients must have a thyroid stimulating hormone (TSH) level and a free thyroxine (free T4) level within the institutional normal limits * Patients must have signed an approved informed consent and authorization permitting release of personal health information * Patients must meet pre-entry requirements as specified * Patients of childbearing potential must have a negative serum pregnancy test prior to the study entry and be practicing an effective form of contraception
Exclusion criteria
* Patients who have had prior therapy with cediranib (AZD 2171) or other VEGF pathway-targeted therapy * Patient with a history of other invasive malignancies, with the exception of non-melanoma skin cancer and other specific malignancies as noted, are excluded if there is any evidence of other malignancy being present within the last three years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy * Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis OTHER THAN for the treatment of endometrial cancer within the last three years are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease * Patients who have received prior chemotherapy for any abdominal or pelvic tumor OTHER THAN for the treatment of endometrial cancer within the last three years are excluded; patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than three years prior to registration, and that the patient remains free of recurrent or metastatic disease * Patients with serious, non-healing wound, ulcer, or bone fracture; this includes history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 28 days prior to the first date of cediranib (AZD 2171) therapy * Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels * Patients with history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures not controlled with standard medical therapy or any brain metastases * Patients with clinically significant cardiovascular disease; this includes: * Uncontrolled hypertension defined as systolic \> 150 mmHg or diastolic \> 100 mmHg despite optimized antihypertensive therapy * Myocardial infarction or unstable angina within 6 months of the first date of cediranib (AZD 2171) therapy * New York Heart Association (NYHA) grade II or greater congestive heart failure or serious cardiac arrhythmia requiring medication; women who have received prior treatment with an anthracycline (including doxorubicin and/or liposomal doxorubicin) and have an ejection fraction \< institutional lower limit of normal (LLN) will be excluded from the study * CTCAE grade 2 or greater peripheral vascular disease * History of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of cediranib (AZD 2171) therapy * Mean corrected QT interval (QTc) \> 500 msec or history of familial long QT syndrome * Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies * Patients undergoing invasive procedures as defined below: * Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to the first date of cediranib (AZD 2171) therapy * Major surgical procedure anticipated during the course of the study * Minor surgical procedures, fine needle aspirates, or core biopsies within 7 days prior to the first date of cediranib (AZD2171) therapy * Patients who are pregnant or nursing
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 | Up to 5 years | Adverse Events (Grade 3 or higher) |
| Progression-free Survival (PFS) = > 6 Months | For disease evaluated by physical examination, progression was assessed prior to each cycle. CT scan or MRI if used to follow lesion for measurable disease every other cycle. Evaluated from time of enrollment until progression or death, up to 5 years | Number of participants who survived for at least 6 months. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v.1.0) as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. |
| Tumor Response | For diesease evaluated by physical examination, response was assessed prior to each cycle. CT scan or MRI if used to follow lesion for measurable disease every other cycle from enrollment until stopping study therapy. The average time on study is 3 mnths | Complete and Partial Tumor Response by RECIST 1.1. Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall response (OR) = CR + PR. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival | Disease that can be assessed by physical exam should be evaluated every cycle. disease assessed by imaging should be evaluated every other cycle. Time frame to determine the date of progression is from the date of enrollment up to 5 years after enrollment | Time until disease progression, death, or date of last contact. |
| Overall Survival | From study entry to death or last contact, up to 5 years. | The observed length of life from entry into the study to death or the date of last contact. |
| Response Without Regard to the Time of Documented Response | Tumor responses with time restriction starts at enrollment and goes to 6 months after enrollment or until pt. off study therapy,whichever occurs first. Without time restriction starts at enrollment,lasts until off study therapy, median duration = 2.63 mth | Complete and partial tumor response by RECIST 1.1 |
Other
| Measure | Time frame | Description |
|---|---|---|
| Levels of Receptor Targets Such as VEGFR (1, 2, 3) and PDGFR | Baseline | — |
| VEGFA Expression on Pre-treatment Tumor Specimens | Baseline | High vs low expression. |
| Plasma Levels of Endogenous Circulating VEGFA, Levels of Its Endogenous Inhibitor, sFlt-1 (the Truncated, Circulating Portion of VEGFR-1), Circulating TF, and Circulating Par-4 | Up to 5 years | — |
| Expression of Phosphorylated ERK1 and 2, c-Jun, Stat3, PKC, and p70S6 Kinase | Baseline | — |
Countries
United States
Participant flow
Recruitment details
The study was activated on 6/7/2010 and suspended to accrual on 3/7/2011. The study reopened on 11/21/2011 and closed on 4/30/2012.
Participants by arm
| Arm | Count |
|---|---|
| Cediranib Cediranib (RECENTIN; AZD2171) will be administered PO 30 mg daily. Each 28 day period will be considered a cycle. Treatment will continue until disease progression or adverse effects prohibit further therapy. | 48 |
| Total | 48 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Inadequate data | 1 |
| Overall Study | Ineligible:Improper pre-protocol therapy | 1 |
| Overall Study | Ineligible:Inadequate pathology | 1 |
| Overall Study | Ineligible: wrong cell type | 1 |
| Overall Study | Never treated | 1 |
Baseline characteristics
| Characteristic | Cediranib |
|---|---|
| Age, Continuous | 64.9 years STANDARD_DEVIATION 9.5 |
| Age, Customized 20-29 years | 0 Participants |
| Age, Customized 30-39 years | 0 Participants |
| Age, Customized 40-49 years | 3 Participants |
| Age, Customized 50-59 years | 10 Participants |
| Age, Customized 60-69 years | 20 Participants |
| Age, Customized 70-79 years | 12 Participants |
| Age, Customized 80-89 years | 3 Participants |
| Sex: Female, Male Female | 48 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 48 / 48 |
| serious Total, serious adverse events | 20 / 48 |
Outcome results
Primary
Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0
Adverse Events (Grade 3 or higher)
Time frame: Up to 5 years
Population: Eligible and treated patients
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cediranib | Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 | Leukopenia | 0 Participants |
| Cediranib | Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 | Thrombocytopenia | 0 Participants |
| Cediranib | Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 | Neutropenia | 0 Participants |
| Cediranib | Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 | Anemia | 3 Participants |
| Cediranib | Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 | Other Investigations | 4 Participants |
| Cediranib | Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 | Other Blood/Lymphatics | 1 Participants |
| Cediranib | Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 | Cardiac | 1 Participants |
| Cediranib | Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 | Ear and labyrinth | 0 Participants |
| Cediranib | Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 | Endocrine | 0 Participants |
| Cediranib | Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 | Eye | 0 Participants |
| Cediranib | Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 | Nausea | 1 Participants |
| Cediranib | Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 | Vomiting | 4 Participants |
| Cediranib | Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 | Other Gastrointestinal | 16 Participants |
| Cediranib | Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 | General and administration site | 13 Participants |
| Cediranib | Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 | Hepatobiliary | 0 Participants |
| Cediranib | Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 | Infections/infestations | 6 Participants |
| Cediranib | Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 | Injury/poisoning | 0 Participants |
| Cediranib | Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 | Metabolism/nutrition | 8 Participants |
| Cediranib | Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 | Musculoskeletal/connective tissue | 3 Participants |
| Cediranib | Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 | Neoplasms benign/malignant | 4 Participants |
| Cediranib | Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 | Peripheral sensory neuropathy | 0 Participants |
| Cediranib | Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 | Nervous system | 1 Participants |
| Cediranib | Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 | Psychiatric | 1 Participants |
| Cediranib | Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 | Renal/urinary | 3 Participants |
| Cediranib | Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 | Reproductive/breast | 1 Participants |
| Cediranib | Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 | Respiratory/thoracic/mediastinal | 4 Participants |
| Cediranib | Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 | Skin/subcutaneous | 0 Participants |
| Cediranib | Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 | Vascular disorders | 18 Participants |
Primary
Progression-free Survival (PFS) = > 6 Months
Number of participants who survived for at least 6 months. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v.1.0) as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: For disease evaluated by physical examination, progression was assessed prior to each cycle. CT scan or MRI if used to follow lesion for measurable disease every other cycle. Evaluated from time of enrollment until progression or death, up to 5 years
Population: Eligible and Treated Patients
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cediranib | Progression-free Survival (PFS) = > 6 Months | 33.3 percentage of participants |
Primary
Tumor Response
Complete and Partial Tumor Response by RECIST 1.1. Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall response (OR) = CR + PR.
Time frame: For diesease evaluated by physical examination, response was assessed prior to each cycle. CT scan or MRI if used to follow lesion for measurable disease every other cycle from enrollment until stopping study therapy. The average time on study is 3 mnths
Population: Eligible and Treated Patients
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cediranib | Tumor Response | 12.5 percentage of participants |
Secondary
Overall Survival
The observed length of life from entry into the study to death or the date of last contact.
Time frame: From study entry to death or last contact, up to 5 years.
Population: Eligible and Treated Patients
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cediranib | Overall Survival | 12.5 months |
Secondary
Progression Free Survival
Time until disease progression, death, or date of last contact.
Time frame: Disease that can be assessed by physical exam should be evaluated every cycle. disease assessed by imaging should be evaluated every other cycle. Time frame to determine the date of progression is from the date of enrollment up to 5 years after enrollment
Population: All eligible and evaluable patients
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cediranib | Progression Free Survival | 3.61 Months |
Secondary
Response Without Regard to the Time of Documented Response
Complete and partial tumor response by RECIST 1.1
Time frame: Tumor responses with time restriction starts at enrollment and goes to 6 months after enrollment or until pt. off study therapy,whichever occurs first. Without time restriction starts at enrollment,lasts until off study therapy, median duration = 2.63 mth
Population: Eligible and Treated Patients
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cediranib | Response Without Regard to the Time of Documented Response | 12.5 percentage of participants |
Other Pre-specified
Expression of Phosphorylated ERK1 and 2, c-Jun, Stat3, PKC, and p70S6 Kinase
Time frame: Baseline
Other Pre-specified
Levels of Receptor Targets Such as VEGFR (1, 2, 3) and PDGFR
Time frame: Baseline
Other Pre-specified
Plasma Levels of Endogenous Circulating VEGFA, Levels of Its Endogenous Inhibitor, sFlt-1 (the Truncated, Circulating Portion of VEGFR-1), Circulating TF, and Circulating Par-4
Time frame: Up to 5 years
Other Pre-specified
VEGFA Expression on Pre-treatment Tumor Specimens
High vs low expression.
Time frame: Baseline